Belongs to

• Solid Tumor Oncology Division

Types of Work

["2022"]

[[["Journal Articles",451],["Meeting Abstracts",431],["Reviews",28],["Editorials",9],["Guidelines",8],["Book Sections",6],["Miscellaneous",6],["Research Letters",6],["Correspondences",2],["Book Wholes",1]]]

[948]

Popular keywords

• adult
• aged
• article
• controlled study
• female
• human
• humans
• major clinical study
• male
• middle aged

Recent Works

1. How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers

   Review

   Stacchiotti, S.; Pantziarka, P.; Leonard, H.; Voltz, C.; Abatedaga, L.; Bouche, G.; Bouygues, C.; Bovée, J. V. M. G.; van der Graaf, W. T. A.; Rojas, T. D.; more...
   Cancer Treatment Reviews (2025)

   Fulltext@MSK | Save
2. A phase 1, first-in-human study of DS-2243, an HLA-A(*)02/NY-ESO-directed bispecific T-cell engager, in patients with advanced solid tumors

   Meeting Abstract

   D'Angelo, S. P.; Subbiah, V.; Blay, J. Y.; Wagner, M. J.; Steeghs, N.; Youk, J.; Mizusako, H.; Ohue, Y.; Jin, J.; Rajper, A. W.; more...
   Journal of Clinical Oncology (2025)

   Fulltext@MSK | Save
3. Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors

   Journal Article

   Milhem, M. M.; Wise-Draper, T. M.; Chandra, S.; Hanna, G. J.; Laux, D. E.; Medina, T. M.; Ansstas, G.; Daud, A.; Kelly, C. M.; O'Day, S. J.; more...
   Journal for ImmunoTherapy of Cancer (2025)

   Fulltext@MSK | Save